求助PDF
{"title":"Incorporating Lymph Node Size at CT as an N1 Descriptor in Clinical N Staging for Lung Cancer.","authors":"Yura Ahn, Sang Min Lee, Jooae Choe, Se Hoon Choi, Kyung-Hyun Do, Joon Beom Seo","doi":"10.1148/radiol.241603","DOIUrl":null,"url":null,"abstract":"<p><p>Background The ninth edition of the TNM classification for lung cancer revised the N2 categorization, improving patient stratification, but prognostic heterogeneity remains for the N1 category. Purpose To define the optimal size cutoff for a bulky lymph node (LN) on CT scans and to evaluate the prognostic value of bulky LN in the clinical N staging of lung cancer. Materials and Methods This retrospective study analyzed patients who underwent lobectomy or pneumonectomy for lung cancer between January 2013 and December 2021, divided into development (2016-2021) and validation (2013-2015) cohorts. The optimal threshold for a bulky LN was defined based on the short-axis diameter of the largest clinically positive LN at CT. Prognostic differences according to presence of bulky LN in cN1 category for overall survival (OS) were evaluated using multivariable Cox analysis. Survival discrimination was assessed using the Harrell concordance index (C-index). Results A total of 3426 patients (mean age, 64.0 years ± 9.3 [SD]; 1837 male) and 1327 patients (mean age, 63.0 years ± 9.7; 813 male) were included in the development and validation cohorts, respectively. The cutoff size for a bulky LN was established at 15 mm, and the presence of bulky LN was an independent risk factor for OS (hazard ratio [HR], 1.54; 95% CI: 1.10, 2.16; <i>P</i> = .01). In the development and validation cohorts, the cN1-bulky group had higher mortality risk than the cN1-nonbulky group (HR, 2.82 [95% CI: 1.73, 4.58; <i>P</i> < .001]; 2.29 [95% CI: 1.34, 3.92; <i>P</i> = .002], respectively). The bulky LN descriptor improved prognostic discrimination within the cN1 category compared with the current staging (C-index from 0.50 to 0.60 and to 0.58 in the development and validation cohorts [<i>P</i> < .001, <i>P</i> = .006], respectively]). Conclusion Defining bulky LN with a size cutoff of 15 mm was an effective descriptor in the clinical staging of N1 lung cancer. © RSNA, 2025 <i>Supplemental material is available for this article.</i> See also the editorial by Horst in this issue.</p>","PeriodicalId":20896,"journal":{"name":"Radiology","volume":"314 1","pages":"e241603"},"PeriodicalIF":12.1000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Radiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1148/radiol.241603","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0
引用
批量引用
Abstract
Background The ninth edition of the TNM classification for lung cancer revised the N2 categorization, improving patient stratification, but prognostic heterogeneity remains for the N1 category. Purpose To define the optimal size cutoff for a bulky lymph node (LN) on CT scans and to evaluate the prognostic value of bulky LN in the clinical N staging of lung cancer. Materials and Methods This retrospective study analyzed patients who underwent lobectomy or pneumonectomy for lung cancer between January 2013 and December 2021, divided into development (2016-2021) and validation (2013-2015) cohorts. The optimal threshold for a bulky LN was defined based on the short-axis diameter of the largest clinically positive LN at CT. Prognostic differences according to presence of bulky LN in cN1 category for overall survival (OS) were evaluated using multivariable Cox analysis. Survival discrimination was assessed using the Harrell concordance index (C-index). Results A total of 3426 patients (mean age, 64.0 years ± 9.3 [SD]; 1837 male) and 1327 patients (mean age, 63.0 years ± 9.7; 813 male) were included in the development and validation cohorts, respectively. The cutoff size for a bulky LN was established at 15 mm, and the presence of bulky LN was an independent risk factor for OS (hazard ratio [HR], 1.54; 95% CI: 1.10, 2.16; P = .01). In the development and validation cohorts, the cN1-bulky group had higher mortality risk than the cN1-nonbulky group (HR, 2.82 [95% CI: 1.73, 4.58; P < .001]; 2.29 [95% CI: 1.34, 3.92; P = .002], respectively). The bulky LN descriptor improved prognostic discrimination within the cN1 category compared with the current staging (C-index from 0.50 to 0.60 and to 0.58 in the development and validation cohorts [P < .001, P = .006], respectively]). Conclusion Defining bulky LN with a size cutoff of 15 mm was an effective descriptor in the clinical staging of N1 lung cancer. © RSNA, 2025 Supplemental material is available for this article. See also the editorial by Horst in this issue.
将CT淋巴结大小作为肺癌临床N分期的N1描述符
第九版TNM肺癌分类修订了N2分类,改善了患者分层,但N1分类的预后异质性仍然存在。目的探讨CT扫描中肿大淋巴结(LN)的最佳截面积,评价肿大淋巴结在肺癌临床分期中的预后价值。材料与方法本回顾性研究分析了2013年1月至2021年12月期间接受肺癌肺叶切除术或全肺切除术的患者,分为发展组(2016-2021)和验证组(2013-2015)。根据CT上最大临床阳性LN的短轴直径来确定大体积LN的最佳阈值。采用多变量Cox分析评估cN1分类中是否存在大体积LN的预后差异。采用Harrell一致性指数(C-index)评估生存歧视。结果共3426例患者(平均年龄64.0岁±9.3岁[SD];男性1837例),1327例(平均年龄63.0岁±9.7岁;813名男性)分别被纳入开发和验证队列。大体积LN的临界值为15 mm,大体积LN的存在是OS的独立危险因素(风险比[HR], 1.54;95% ci: 1.10, 2.16;P = 0.01)。在研究和验证队列中,cn1肥大组的死亡风险高于cn1非肥大组(HR, 2.82) [95% CI: 1.73, 4.58;P < .001];2.29 [95% ci: 1.34, 3.92;P = .002])。与当前分期相比,庞大的LN描述符改善了cN1类别的预后判别(C-index在开发和验证队列中分别从0.50到0.60和0.58 [P < .001, P = .006])。结论以15mm大小的淋巴结划分是N1型肺癌临床分期的有效指标。©RSNA, 2025本文可获得补充材料。参见本期霍斯特的社论。
本文章由计算机程序翻译,如有差异,请以英文原文为准。